CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aridis Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aridis Pharmaceuticals Inc
983 University Avenue, Bldg. B
Phone: (408) 385-1742p:408 385-1742 LOS GATOS, CA  95032  United States Ticker: ARDSARDS
Business Summary
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes-YesYes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Founder, Executive Chairman of the Board EricPatzer 5/1/2014 1/1/2003
Chief Executive Officer, Co-Founder, Chief Scientific Officer, Director VuTruong 59 1/1/2003 1/1/2003
Chief Medical Officer HasanJafri 56 6/1/2020 6/1/2020
Independent Director JohnHamilton 78 6/1/2015 6/1/2015
Independent Director SusanWindham- Bannister 73 6/1/2019 6/1/2019

Business Names
Business Name
ARDS
Aridis Biopharmaceuticals LLC
Aridis Pharmaceuticals C.V.

General Information
Number of Employees: 37 (As of 12/31/2022)
Outstanding Shares: 44,574,021 (As of 11/2/2023)
Shareholders: 72
Stock Exchange: OTC
Federal Tax Id: 472641188
Fax Number: (408) 960-3822
Email Address: edwardsr@aridispharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024